Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Radiolabeled OTSA101-DTPA in Relapsed/Refractory Synovial Sarcoma
jRCT2080224960Phase 1Terminated
- Sponsor
- OncoTherapy Science, Inc.
- Start
- Nov 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tabituximab barzuxetan in synovial sarcoma (SS), sponsored by OncoTherapy Science, Inc. Started Nov 2019; status: terminated.
02
Drugs
tabituximab barzuxetan
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on jRCT2080224960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224960.